MSCLF Message Board Post 9833596 | iCo Therapeutics
home / stock / msclf / msclf message board
Kem51
(investorshub)
Posted on: Dec/09/2021 15:04:03
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167061801
Effective Dec. 10,2021 ICOTF will change to MSCLF.
News, Short Squeeze, Breakout and More Instantly...
-
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
-
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...
-
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSC...